Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC
Meeting Coverage > > MHNCS-- Local control in 91% of cases at 1 year in little potential trial
by Charles Bankhead, Senior Editor, MedPage Today March 1, 2024
More than 90% of clients with in your area sophisticated basal cell cancer (BCC) of the head and neck attained locoregional control (LRC) with vismodegib (Erivedge) and radiation treatment (RT), a little scientific trial revealed.
LRC at 1 year was 91% after vismodegib induction treatment followed by concurrent vismodegib and RT. The general action rate was 63% after induction and 83% after concurrent treatment.
After a mean follow-up of 5.7 years, both progression-free survival (PFS) and general ...